R2WA.F BEXIMCO PHARMA.GDR REGS 1
- Market cap
- EUR 279M
- P/E
- 3.6x
- P/B
- 0.32x
- ROE
- 15.4%
- Dividend yield
- 8.41%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Mar 2026.
Is R2WA.F undervalued?
Graham numberThe Graham number of BEXIMCO PHARMA.GDR REGS 1 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BEXIMCO PHARMA.GDR REGS 1 fundamental analysis
No fundamental analysis for BEXIMCO PHARMA.GDR REGS 1 yet.
BEXIMCO PHARMA.GDR REGS 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh and internationally. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin an…
Full company profileBEXIMCO PHARMA.GDR REGS 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BEXIMCO PHARMA.GDR REGS 1 annual financial statements (BDT; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 29.5B | 34.7B | 39.3B | 44.4B | 49.1B | 55.2B |
| Gross Profit | 13.9B | 15.8B | 17.3B | 19.6B | 22.3B | 27.1B |
| Operating Income | 6.66B | 6.85B | 7.17B | 8.59B | 9.62B | 12.2B |
| EBITDA | - | 9.28B | 9.37B | 10.6B | 12.0B | 14.3B |
| Net Income | 5.13B | 5.12B | 4.61B | 5.83B | 6.94B | 9.25B |
| EPS | 11 | 11 | 10 | 13 | 16 | 21 |
| Balance Sheet | ||||||
| Total Assets | 52.2B | 66.1B | 69.2B | 69.3B | 73.2B | 78.7B |
| Total Liabilities | 14.9B | 21.5B | 21.5B | 17.4B | 16.2B | 14.6B |
| Shareholders' Equity | 37.0B | 40.6B | 43.7B | 47.9B | 53.1B | 60.0B |
| Cash & Short-term Investments | 675M | 1.17B | 1.14B | 854M | 1.70B | 4.23B |
| Cash Flow | ||||||
| Operating Cash Flow | - | 5.21B | 6.08B | 8.36B | 7.22B | - |
| Capital Expenditure | 2.56B | 2.94B | 2.71B | 2.23B | 3.03B | 3.93B |
| Free Cash Flow | 3.46B | 2.27B | 3.37B | 6.13B | 4.19B | 6.02B |
| Ratios | ||||||
| ROE | 13.8% | 12.6% | 10.6% | 12.2% | 13.1% | 15.4% |
| ROA | 9.8% | 7.7% | 6.7% | 8.4% | 9.5% | 11.8% |
| Net Profit Margin | 17.4% | 14.8% | 11.8% | 13.1% | 14.1% | 16.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BEXIMCO PHARMA.GDR REGS 1 dividends
- Dividend yield
- 8.41%
- Forward dividend
- -
- Payout ratio
- 23.1%
- Ex-dividend date
- Jul 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | BDT 1.60B | 3.59 | 23.1% |
| 2024 | BDT 1.59B | 3.55 | 27.2% |
| 2023 | BDT 1.57B | 3.51 | 34.0% |
| 2022 | BDT 1.62B | 3.64 | 31.7% |
| 2021 | BDT 578M | 1.30 | 11.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.1:1 on Nov 23, 2020.
Who owns BEXIMCO PHARMA.GDR REGS 1
- Insiders 0.00%
- Institutions 0.21%
- Public & others 99.79%
- Shares outstanding 446M
- Free float 312M
BEXIMCO PHARMA.GDR REGS 1 company profile
- Company name
- BEXIMCO PHARMA.GDR REGS 1
- Ticker
- R2WA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6,000
- Fiscal year end
- June
- Address
- 19 Dhanmondi R/A, Dhaka, Bangladesh, 1205
- Phone
- 880 2 5861 1001
- Website
- beximcopharma.com
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh and internationally. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. Beximco Pharmaceuticals PLC. was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
BEXIMCO PHARMA.GDR REGS 1 management
7- Mr. Mohammad Ali Nawaz C.M.A.Chief Financial Officer
- Mr. S. M. Rabbur RezaChief Operating Officer
- Mr. Jamal Ahmed ChoudhuryDirector of Accounts & Finance
- Mr. Rizvi Ul KabirDirector of Marketing
- Mr. M. A. Arshad BhuiyanGeneral Manager of Human Resources
- Mr. Zakaria Seraj ChowdhuryHead of Distribution Services & Director of International Marketing
- Mr. Mohammad Asad Ullah FCSCompany Secretary & Executive Director